title: Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells.
abstract: Search for new substances with antiproliferative activity and apoptosis inducing potential towards HepG2 cells is important since HCC is notoriously resistant to conventional chemotherapy. Dietary phytochemicals with significant anti-proliferative and apoptosis inducing potential are considered as agents promising for cancer therapy. Naringenin, a common dietary flavonoid abundantly present in fruits and vegetables, is believed to possess strong cytotoxic activity in numerous types of cancer cells. However, the detailed molecular mechanisms of its antiproliferative effects and apoptosis induction are still unclear. In this study, we investigated antiproliferative and apoptosis-inducing effect of naringenin in human hepatocellular carcinoma HepG2 cells. Naringenin was shown to inhibit the proliferation of HepG2 cells resulted partly from an accumulation of cells in the G0/G1 and G2/M phase of the cell cycle. Naringenin induced a rapid accumulation of p53, which might account for the naringenin-induced G0/G1 and G2/M phase arrests in Hep G2 cells. In addition, naringenin have been shown to induce apoptosis as evidenced by nuclei damage and increased proportion of apoptotic cells detected by flow cytometry analysis. Naringenin triggered the mitochondrial-mediated apoptosis pathway as shown by an increased ratio of Bax/Bcl-2, subsequent release of cytochrome C, and sequential activation of caspase-3. Our results showed that naringenin had inhibitory effect on the growth of HepG2 cell line through inhibition of cell proliferation and apoptosis induction. The elucidation of the drug targets of naringenin on inhibition of tumor cells growth should enable further development of naringenin for liver cancer therapy.
authors: Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, 608 002, Tamil Nadu, India, sent.biochem@gmail.com.
authors: Duraikannu
authors: D
authors: Arul
authors: Perumal
authors: P
authors: Subramanian
mesh_terms: D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects; D048708:Cell Growth Processes / Q000187:drug effects; D044950:Flavanones / Q000494:pharmacology*; D056945:Hep G2 Cells; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D044950:Flavanones; C005273:naringenin
references: Future Oncol. 2010 Oct;6(10):1545-50
references: 21062154
references: Nature. 1970 Aug 15;227(5259):680-5
references: 5432063
references: Onkologie. 2008 Oct;31(10):550-5
references: 18854656
references: Food Chem Toxicol. 2008 Dec;46(12):3684-90
references: 18930780
references: Nutr Cancer. 2011;63(3):444-55
references: 21391128
references: Nutr Cancer. 2000;38(1):116-22
references: 11341036
references: World J Gastroenterol. 2011 Apr 7;17(13):1685-9
references: 21483627
references: Integr Biol (Camb). 2011 Apr;3(4):279-96
references: 21340093
references: Asian Pac J Cancer Prev. 2011;12(6):1555-9
references: 22126498
references: Expert Opin Investig Drugs. 2010 Feb;19(2):265-74
references: 20074016
references: J Cell Physiol. 2006 Oct;209(1):13-20
references: 16741928
references: J Nutr Biochem. 2012 Apr;23(4):368-78
references: 21543203
references: Protein Cell. 2011 Jun;2(6):507-16
references: 21748601
references: Toxicol In Vitro. 2009 Mar;23(2):259-65
references: 19124070
references: Chem Biol Interact. 2011 Jan 15;189(1-2):26-36
references: 20932960
references: Rev Med Chir Soc Med Nat Iasi. 2010 Oct-Dec;114(4):1209-14
references: 21500482
references: Nutr Res. 2008 Feb;28(2):106-12
references: 19083396
references: Cancer Chemother Pharmacol. 2012 Mar;69(3):799-805
references: 22037880
references: Adv Exp Med Biol. 2010;698:36-51
references: 21520702
references: Biol Pharm Bull. 2007 Dec;30(12):2394-8
references: 18057732
references: Blood. 1994 Sep 1;84(5):1415-20
references: 8068938
references: Anal Biochem. 1976 May 7;72:248-54
references: 942051
references: Nutr Cancer. 2011;63(4):495-505
references: 21500099
references: Exp Toxicol Pathol. 2010 Mar;62(2):171-81
references: 19409769
references: J Food Sci. 2011 Apr;76(3):T77-83
references: 21535865
references: Ther Umsch. 2011 Apr;68(4):213-7
references: 21452143
references: Cell Death Differ. 2011 Sep;18(9):1414-24
references: 21415859
references: Oncogene. 2001 Apr 5;20(15):1803-15
references: 11313928
references: Zhong Yao Cai. 2007 Aug;30(8):980-4
references: 18074851
references: Dev Cell. 2011 Jul 19;21(1):92-101
references: 21763611
references: Oncologist. 2010;15 Suppl 4:34-41
references: 21115579
references: J Biomed Biotechnol. 2011;2011:978312
references: 21765642
references: J Agric Food Chem. 2011 Mar 23;59(6):2314-23
references: 21338095
references: Nat Rev Cancer. 2011 Mar;11(3):211-8
references: 21326325
references: Cardiovasc Hematol Agents Med Chem. 2011 Apr 1;9(2):62-77
references: 21644918
references: Eur J Pharmacol. 2011 Sep 30;667(1-3):50-5
references: 21497161